Mesenchymal stem cell-derived small extracellular vesicles promote neuroprotection in rodent models of glaucoma by Mead, Ben et al.
Glaucoma
Mesenchymal Stem Cell–Derived Small Extracellular
Vesicles Promote Neuroprotection in Rodent Models of
Glaucoma
Ben Mead,1 Juan Amaral,2 and Stanislav Tomarev1
1Section of Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National
Institutes of Health, Bethesda, Maryland, United States
2Unit on Ocular Stem Cell & Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland,
United States
Correspondence: Ben Mead, Section
of Retinal Ganglion Cell Biology,
Laboratory of Retinal Cell and Mo-
lecular Biology, National Eye Insti-
tute, National Institutes of Health,
Bethesda, Maryland, 20892, USA;
ben.mead@nih.gov.
Stanislav Tomarev, Section of Retinal
Ganglion Cell Biology, Laboratory of
Retinal Cell and Molecular Biology,
National Eye Institute, National In-
stitutes of Health, Bethesda, Mary-
land, 20892, USA;
TomarevS@nei.nih.gov.
Submitted: August 23, 2017
Accepted: January 4, 2018
Citation: Mead B, Amaral J, Tomarev S.
Mesenchymal stem cell–derived small
extracellular vesicles promote neuro-
protection in rodent models of glau-
coma. Invest Ophthalmol Vis Sci.
2018;59:702–714. https://doi.org/
10.1167/iovs.17-22855
PURPOSE. To investigate the benefit of bone marrow mesenchymal stem cell (BMSC)-derived
small extracellular vesicles (sEV) as an intravitreal (ivit) therapy in two rat models of glaucoma
and to determine and identify candidate miRNA involved in the mechanism.
METHODS. sEV were isolated from human BMSC and fibroblasts and ivit injected into adult rats
after induction of elevated IOP. IOP was elevated using either intracameral injection of
microbeads or laser photocoagulation of circumferential limbal vessels and the trabecular
meshwork. Retinal nerve fiber layer (RNFL) thickness was measured using optical coherence
tomography, positive scotopic threshold response (pSTR) recorded using ERG, and RNA
binding protein with multiple splicing (RBPMSþ) retinal ganglion cell (RGC) counted using
retinal wholemounts. sEV miRNA were sequenced using RNAseq.
RESULTS. sEV isolated from BMSC promoted significant neuroprotection of RGC while
preventing RNFL degenerative thinning and loss of pSTR. sEV proved therapeutically
efficacious when ivit injected every week or every month, but ineffective with longer delays
between treatments. Knockdown of Argonaute2 (AGO2), a protein critical for miRNA
function and packing into sEV prior to sEV isolation, significantly attenuated the above
effects. Addition of BMSC sEV (but not fibroblast sEV) reduced death of cultured purified
RGC. RNAseq identified 43 miRNA upregulated in BMSC sEV in comparison to fibroblast sEV,
which yielded no neuroprotective effects.
CONCLUSIONS. Injection of BMSC-derived sEV into the vitreous provided significant therapeutic
benefit to glaucomatous eyes. The neuroprotective effect of sEV, at least partially, may be
explained by direct action on RGC through miRNA-dependent mechanisms.
Keywords: glaucoma, mesenchymal stem cells, extracellular vesicles, exosomes, retinal
ganglion cells, miRNA
Glaucoma is one of the world’s leading causes of irreversibleblindness and is characterized by the slow progressive
degeneration of retinal ganglion cells (RGC) and their axons.1
RGC operate as the final stage in the phototransductive visual
pathway of the retina, tasked with the projection of electro-
chemical information to the brain along their axons, which
make up the optic nerve. RGC are irreplaceable, making their
dysfunction and subsequent loss a severe detriment to vision
and thus, quality of life. While current therapies can
successfully reduce IOP, the critical risk factor associated with
glaucoma, no neuroprotective strategies currently exist.
Mesenchymal stem cells (MSC) are a multipotent stromal
cell residing in mesenchymal tissues such as bone marrow
(BMSC),2 adipose (ADSC),3 umbilical blood (UCB-MSC),4 and
dental pulp.5 Their neuroprotective efficacy in retinal injury
models has been demonstrated by us6–9 as well as independent
research groups,10–12 and are currently undergoing clinical
trials for retinal degenerative diseases such as glaucoma.13 The
mechanism of action is exclusively paracrine, through the
secretion of neuroprotective factors as opposed to RGC
replacement. MSC secrete a large abundance of factors, of
which several neuroprotective candidates have been identified
including brain-derived neurotrophic factor (BDNF) and plate-
let-derived growth factor (PDGF).7,14
Extracellular vesicles (EV) include exosomes, microvesicles,
and apoptotic bodies and were described decades ago as being
secreted from most cell types both by outward budding of the
plasma membrane as well as intracellular formation within
multivesicular endosomes before secretion into the extracellu-
lar space.15 The formation of the vesicle as well as the loading
of cargo is reliant on a complex of 30 proteins referred to as
Endosomal Sorting Complex Required for Transport (ESCRT).
Exosomes contain mRNA, miRNA, lipids, and protein and can
be easily isolated from various bodily fluids as well as
conditioned medium in vitro.15,16 Exosomes are typically
defined by their size of less than 150 nm although a 220 nm
threshold is often used as the sample is passed through 220-nm
porous filter.17 As this preparation includes nonexosomal EV,
this population will be referred to as small EVs (sEV) from this
point. Originally thought to be a mechanism solely for the
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removal of waste, sEV have now been demonstrated to deliver
their cargo to nearby cells that translate the mRNA into
proteins, as well as have gene expression downregulated by
the sEV-derived miRNA.18 Therefore, irrespective of the
receptors a recipient cell expresses, gene expression can be
regulated by sEV-mediated cell-to-cell communication.
miRNA are small RNA molecules that are processed and
incorporated into the RNA-induced silencing complex (RISC)
composed of Dicer, TRBP, and Argonaute2 (AGO2), its catalytic
center.19 Binding of the miRNA to the 30 untranslated region of
mRNA leads to repression of translation and a single miRNA
can repress the translation of several hundred mRNA. AGO2 is
integral to miRNA function as well as to the packaging of
miRNA into sEV.20 Interestingly, the function of exosomal
miRNA is dependent on AGO2 derived from the origin cell/sEV,
AGO2 in the recipient cell is not involved in the exosomal-
derived miRNA function. Therefore, knockdown of AGO2 in
host cells allows the isolation and testing of miRNA-depleted
sEV.21,22
The secretome of BMSC is responsible for their therapeutic
efficacy and exosomes/sEV, considered part of the secretome,
have been proposed to orchestrate some of these effects.23–25
Interestingly, MSC sEV are enriched for select miRNA relative to
MSC, suggesting the loading and packaging of RNA into sEV is
an active and specific process.26 Several studies have begun to
test MSC sEV in a variety of disease models including ocular
pathologies. Intravenous BMSC sEV treatment in a mouse
model of experimental autoimmune uveitis prevented signifi-
cant retinal structural damage, inflammatory cell infiltration,
and proinflammatory cytokine elevation.27 BMSC-derived sEV
were found to be just as effective as BMSC, suggesting they are
the active component mediating the therapeutic effect.
Similarly, periocular injections of MSC sEV in rats with
experimental autoimmune uveitis reduced the infiltration of
T cell subsets and other inflammatory cells in the eyes.28
In a mouse model of diabetic nephropathy, systemic
administration of BMSC, BMSC-conditioned medium, or
BMSC-derived sEV elicited a therapeutic effect and promoted
survival of tubular epithelial cells.29 Intravitreal (ivit) injections
of MSC-derived sEV in mice ameliorated retina laser injury
partially by inhibition of monocyte chemotactic protein.30
In many cases, the therapeutic effects elicited by BMSC sEV
have been attributed to their miRNA cargo. In a mouse model
of myocardial infarction, intravenous,31 or subcutaneous32
delivery of MSC sEV improved angiogenesis and subsequent
cardiac function. This effect was mediated through miRNA and
in particular, miRNA-210 and its interaction with the gene
Efna3.32 An in vitro study demonstrated that UCB-MSC– and
BMSC-derived sEV protect kidney tubular epithelial cells
through the action of miRNA including MIR-23A, MIR-126,
and MIR-296.33 In line with these observations, our previous
study showed that BMSC sEV demonstrate a significant
neuroprotective effect on injured RGC after optic nerve crush
(ONC), an effect that was abrogated following the depletion of
miRNA from sEV.22
The present study aimed to test BMSC sEV in a more
clinically relevant setting by using two rat models of glaucoma,
and aimed to determine candidate miRNA responsible for this
effect.
METHODS
Animals
Adult female outbred Sprague-Dawley rats weighing 150 to 200
g (Charles River, Wilmington, MA, USA) were maintained in
accordance with guidelines described in the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research,
using protocols approved by the National Eye Institute
Committee on the Use and Care of Animals.
Animals were kept at 218C and 55% humidity under a 12-
hours light and dark cycle, given food/water ad libitum and
were under constant supervision from trained staff. Animals
were euthanized by rising concentrations of CO2 before
extraction of retinae.
Materials
All reagents were purchased from Sigma (Allentown, PA, USA)
unless otherwise specified.
BMSC Cultures
Human CD29þ/CD44þ/CD73þ/CD90þ/CD45 BMSC (con-
firmed by supplier; Lonza, Walkersville, MD, USA) from three
donors were pooled and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 1% penicillin/streptomy-
cin and 10% exosome-depleted fetal bovine serum (Thermo
Fisher Scientific, Cincinnati, OH, USA). Cell cultures were
maintained at 378C in 5% CO2 with medium changed every 3
days and cells passaged with 0.05% trypsin/EDTA when 80%
confluent. Human dermal fibroblasts (Lonza) were grown in
the above conditions and used as a control. For all experi-
ments, BMSC and dermal fibroblasts were used at passage two
through five.
Transfection and Confirmation of Knockdown
For a subgroup of animals, BMSC were transfected using
Lipofectamine 3000 (Thermo Fisher) per the manufacturer’s
protocol. Briefly, 70% confluent BMSC grown in Opti-MEM
medium were incubated with Lipofectamine 3000 reagent and
either siRNA against AGO2 (SiAgo2, #4392420/assay id s25931;
Thermo Fisher Scientific) or a scrambled control siRNA
(#4390843; SiScr) for 48 hours. AGO2 knockdown (>70%)
was confirmed by Western blotting like previously described22
(Supplementary Fig. S1).
Exosome/sEV Isolation and Quantification
Exosomes were isolated from BMSC and fibroblasts using
ExoQuick-TC (System Biosciences, Mountain View, CA, USA)
per the manufacturer’s instructions. Briefly, conditioned
medium was centrifuged at 3000g for 15 minutes to remove
cells and debris, incubated with ExoQuick reagent overnight at
48C (1:10 ratio with medium), centrifuged at 1500g for 15
minutes a final time before the exosome pellet is resuspended
in sterile PBS. The exosome preparation is passed through a
0.22-lm filter to remove any large extracellular vesicles
(microvesicles and apoptotic bodies). Because it is expected
some nonexosomal vesicles remain in the preparation, we
refer to the exosomes used in this study as sEV. Using Western
blot, exosomes were characterized by their positive staining for
the exosome/sEV markers Syntenin-1 and CD63 and negative
staining for high-/low-density lipoprotein markers ApoA1 and
ApoB (Supplementary Fig. S2). Briefly, sEV were lysed in
passive lysis buffer (#E1531; Promega, Madison, WI, USA)
before protein concentration was determined by BCA protein
assay (Thermo Fisher). Protein samples (20 lg) were separated
on 4% to 12% Bis-Tris protein gels at 150 V for 40 minutes.
Proteins were transferred to polyvinylidene fluoride mem-
branes, blocked in 10% Western blot blocking buffer (Roche,
Basel, Switzerland) in Tris-buffered saline (TBS), stained
overnight in primary antibody (Table 1) diluted in TBS, washed
3 3 5 minutes in TBST, stained for 1 hour with secondary
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antibody (Table 1) in TBS, washed 3 3 5 minutes in TBST
before detection with Immobilon ECL reagents (Millipore,
Burlington, MA, USA). Densitometry of Western blot bands
were analysed using ImageJ software (http://imagej.nih.gov/ij/;
provided in the public domain by the National Institutes of
Health, Bethesda, MD, USA). sEV were derived from BMSC
pooled from 3 donors and this pooled sample of sEV was
assayed in triplicate by Western blot and used throughout the
remainder of the study.
The concentration and size distribution of sEV were
characterized using a NanoSight LM10 instrument (Malvern,
Worcester, MA, USA), equipped with a 405 nm LM12 module
and EM-CCD camera (DL-658-OEM-630; Andor, Concord, MA,
USA). Three videos were captured per sample with a camera
level of 10. Videos were analyzed with a detection threshold of
two, automatic blur size and 12.9- to 13.1-pix maximum jump
size. Slider gain was set to 80 and a total of 567 frames were
taken.
Isolation, Purification, and Culture of Retinal
Ganglion Cells
Eight well chamber slides (Thermo Fisher Scientific) were
precoated with 100 lg/mL poly-D-lysine for 60 minutes and
then with 20 lg/mL laminin for 30 minutes. After culling and
ocular dissection, the retinae of female Sprague-Dawley were
minced in 1.25 mL of papain (20 U/mL; as per manufacturer’s
instructions, #LK003150; Worthington Biochem, Lakewood,
NJ, USA) containing 50 lg/mL of DNase I (62.5 lL;
Worthington Biochem) and incubated for 90 minutes at 378C.
The retinal cell suspension was centrifuged at 300g for 5
minutes and the pellet resuspended in 1.575 mL of Earle’s
balanced salt solution (Worthington Biochem) containing 1.1
mg/mL of reconstituted albumin ovomucoid inhibitor (150 lL;
Worthington Biochem) and 56 lg/mL of DNase I (75 lL). After
adding to the top of 2.5 mL of albumin ovomucoid inhibitor
(10 mg/mL) to form a discontinuous density gradient, the
retinal cell suspension was centrifuged at 70g for 6 minutes
and the cell pellet resuspended in 1 mL of PBS.
RGC were purified from the retinal suspension using
CD90.1 magnetic beads as per the manufacturer’s instructions
(#130-096-209; Miltenyi Biotec, Auburn, CA, USA). Briefly,
retinal cells are incubated with CD90.1 enrichment and CD11b
depletion antibodies conjugated to magnetic beads. Following
depletion, the retinal suspension is passed through a magne-
tized column and the enriched RGC are collected and plated at
a density 5000 RGC/well in supplemented Neurobasal-A (25
mL Neurobasal-A [Thermo Fisher Scientific], 1X concentration
of B27 supplement [Life Technologies, Carlsbad, CA, USA], 0.5
mM of L-glutamine [62.5 lL; Thermo Fisher Scientific], and 50
lg/mL of gentamycin [125 lL; Thermo Fisher Scientific]). We
confirmed a >99% RGC purity by immunocytochemistry,
staining for RBPMS (data not shown).
In Vivo Experimental Design
The experimental design is shown schematically in Figure 1A.
Seventy rats were divided into three groups: Group 1 consisted
of five uninjured/untreated animals; Group 2 consisted of 30
rats with ocular hypertension induced by intracameral (ic)
injection of microbeads; Group 3 consisted of 35 rats with
ocular hypertension induced by laser photocoagulation of the
trabecular meshwork (TM) and limbal vessels. Induction of the
model as well as treatment with ivit sEV (BMSC or fibroblasts)
were performed bilaterally and began on day 0 with some
animals further receiving a weekly treatment. While it is not
possible to treat Group 3 monthly, as the experimental length
is 21 days, Group 2, which is a 56-day experiment also received
monthly injections. Along with BMSC and fibroblast sEV
treatments, Group 3 also received sEV derived from MSC
transfected with SiAgo2 or SiScr. To make up for any animals/
tissue that were unusable at the end of the study (due to animal
deaths, surgical problems, lack of ocular hypertension, or
wholemounting errors), additional animals were run to ensure
each treatment subgroup was made up of five animals/10 eyes.
Induction of Ocular Hypertension With
Intracameral Microbeads
Ocular hypertension was induced in Group 2 by ic injection of
microbeads as previously described.34 Anesthesia was induced
with 5% Isoflurane (Baxter Healthcare Corp, Deerfield, IL,
USA)/1.5 L per minute O2 and maintained at 3.5% throughout
the procedure. Using a 158 blade (Fine Science Tools, Reading,
PA, USA) a small 2-mm incision was made at the peripheral
cornea and aqueous humour was allowed to exude. Using the
same incision site, a 10-lL solution of microbeads was
administered with a glass micropipette, produced in-house
from a glass capillary rod (Harvard Apparatus, Kent, UK) using
a Flaming-Brown micropipette puller (Sutter Instruments,
Novato, CA, USA). The microbead solution was loaded into
the microneedle immediately before injection and consisted of
5 lL of 6-lm beads (polybead polystyrene, Cat#07312;
Polysciences, Inc., Warrington, PA, USA) followed by 5 lL of
10-lm beads (polybead polystyrene, Cat#17136; Polysciences,
Inc.), both at concentrations of 2 3 108/mL. Administration
was made slowly and the needle was retracted with a 2-minute
delay to minimize leakage. Due to the variable translucency of
TABLE 1. Antibodies Used in Immunohistochemistry (IHC), Immunocytochemistry (ICC), and Western Blot (WB)
Antigen Dilution Supplier Catalogue No.
RBPMS 1:500 (IHC) Thermo Fisher #ABN-1376
bIII-tubulin 1:500 (ICC) Sigma #T-8660
AGO2 1:1000 (WB) Thermo Fisher #MA5-14861
Syntentin-1 1:1000 (WB) Abcam (Cambridge, MA, USA) #Ab133267
CD63 1:1000 (WB) System Biosciences #Exoab-CD63-A1
ApoA1 1:1000 (WB) Abcam #ab7613
ApoB 1:1000 (WB) Abcam #ab20737
HSC70 1:5000 (WB) Santa Cruz (Dallas, TX, USA) #sc-7298
Mouse IgG HRP 1:2000 (WB) GE Healthcare (Waldorf, MD, USA) #NA-931
Guinea Pig IgG 546 1:400 (IHC) Thermo Fisher #A-11074
Mouse IgG 488 1:400 (ICC) Thermo Fisher #A-11001
Mouse IgG HRP 1:2000 (WB) GE Healthcare #NA-931
Rabbit IgG HRP 1:10,000 (WB) Cell Signaling (Danvers, MA, USA) #7074
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FIGURE 1. Experimental design of study and exosome isolation. (A) Timeline and groupings of study, detailing the number of animals (eyes) per
group, the two glaucoma models used and the sEV treatment schedule. (B) Nanosight analysis of extracellular vesicles isolated from BMSC,
demonstrating their size and relative quantity.
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the eye after microbead injection, reliable ERG and optical
coherence tomography (OCT) measurements were not possi-
ble.
Induction of Ocular Hypertension With Laser
Photocoagulation
Ocular hypertension was induced in Group 3 by laser
photocoagulation of the TM and circumferential limbal vessels
as previously described.35 Anesthesia was induced with
intraperitoneal injection of ketamine (100 mg/kg; Putney,
Inc., Portland, ME, USA)/xylazine (10 mg/kg; Lloyd, Inc.,
Shenandoah, IA, USA). Pupil constriction and subsequent
opening of the iridocorneal angle was achieved with 4%
pilocarpine hydrochloride ophthalmic solution (Sandoz,
Princeton, NJ, USA). An OcuLight GLx 532-nm laser (Iridex,
Mountain View, CA, USA) was used to deliver laser burns at 0.3
W, at a spot size of 100 lm, and duration of 0.5 seconds. Three
locations were photocoagulated: approximately 2708 of the
circumferential limbal vessels, episcleral veins branching from
these limbal vessels, and finally, a transscleral/transcorneal
3608 burn of the TM/iridocorneal angle. Nasal vasculature was
left uninjured to prevent ischemia.
Intraocular Pressure Recording
IOP were recorded for all rats using a Tonolab rebound
tonometer (Colonial Medical Supply, Franconia, NH, USA). IOP
was recorded under isoflurane-induced anesthesia during the
same 3- hour window each day, sampled 18 times and averaged
for each individual recording.
Intravitreal Delivery of sEV
Under isoflurane-induced anesthesia, sEV were injected into
the vitreous, just posterior to the limbus using glass
micropipette. A 5-lL volume of sterile phosphate-buffered
saline (sPBS) loaded with 33 109 sEV was injected slowly and
the needle was retracted after a 1-minute delay to minimize
backflow. The concentration was chosen based on our
previous study22 that demonstrated efficacy.
Electroretinography Measurements of the Positive
Scotopic Threshold Response
ERG was recorded using the Espion Ganzfeld full-field system
(Diagnosys LLC, Lowell, MA, USA) on day 0 before induction of
ocular hypertension, and on day 56/21 (Groups 2 and 3,
respectively) before animals were killed. Rats were dark
adapted for 12 hours overnight and prepared for ERG
recording under dim red light (>630 nm). Anesthesia was
induced with intraperitoneal injection of ketamine/xylazine
and eyes dilated with tropicamide. Scotopic flash ERG was
recorded from 5.5 to þ10 log units with respect to standard
flash in half log-unit steps. ERG traces were analyzed using in
built Espion software and the amplitude (with respect to
baseline) was used as a measure of rat visual function. Traces at
a light intensity of 13 105 mcd/s were chosen for analysis as
they gave a clean, unambiguous pSTR 100 ms after stimulus.
An individual masked to the treatment groups performed all
readings and analysis.
Optical Coherence Tomography Measurements of
the Retinal Nerve Fiber Layer
OCT was performed on rats under anesthesia (intraperitoneal
ketamine/xylazine) on day 0 before induction of ocular
hypertension, and on day 56/21 (Groups 2 and 3, respectively)
before animals were killed. A Spectralis HRA3 confocal
scanning laser ophthalmoscope (Heidelberg Engineering,
Heidelberg, Germany) was used to take images of the retina
around the optic nerve head and in-built software segmented
the retinal nerve fiber layer (RNFL) and quantified the
thickness. Segmentation was manually adjusted (by an
individual masked to the treatments groups) when necessary
to prevent inclusion of blood vessels that populate the RNFL.
RGC Counts in Retinal Wholemounts
Rats were euthanized at 56/21 days (Groups 2 and 3,
respectively) by rising concentration of CO2, and perfused
intracardially with 4% paraformaldehyde (PFA) in PBS. Eyes
were enucleated and retinae dissected and immersion post-
fixed in 4% PFA for 1 hour at 48C. Wholemounted retinae were
permeabilized in 0.5% Triton X-100 in PBS for 15 minutes at
708C, washed in fresh Triton X-100 for a further 15 minutes
before incubation with primary antibody diluted in whole-
mount antibody diluting buffer (wADB2% bovine serum
albumin, 2% Triton X-100 in PBS) overnight at 48C and, the
following day, were washed 3 3 10 minutes in PBS and
incubated with secondary antibodies in wADB for 2 hours at
room temperature. After 2 hours, retinae were washed for 33
10 minutes in PBS and mounted vitreous side up on superfrost
glass slides (Superfrost Plus; Fisher Scientific, Pittsburgh, PA,
USA), facilitated by four equidistant cuts into the peripheral
retina. Slides were allowed to air dry before mounting in
Vectorshield medium (Vector Laboratories, Peterborough, UK)
and applying cover slips. The antibodies used are detailed in
Table 1.
FIGURE 2. IOP measurements in the two glaucoma models. (A) Mean
6 SEM IOP (mm Hg) of healthy animals (green) and animals receiving
ic injection of microbeads and ivit sEV treatments. (B) Mean IOP of
healthy animals (green) and animals receiving laser photocoagulation
of the trabecular meshwork/limbal vessels and ivit sEV treatments.
Asterisks represent significant difference between intact/control and
experimental groups (P < 0.05).
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Retinal wholemounts were imaged using a Z1 Imager
epifluorescent microscope and Axiocam HRc camera (Carl
Zeiss, Inc., Thornwood, NY, USA) and RNA binding protein
with multiple splicing (RBPMS)þ cells were counted in three
0.33-mm2 regions per retinal quadrant at 1, 2, and 3 mm from
the optic nerve head (see Fig. 3C). An individual masked to the
treatment group conducted counts manually. The mean
number of RGC/image was derived from the 12 images, which
made up 2.6% of the total retina (50 mm2)36 and was used to
calculate RGC/mm2 with each group consisting of 10 retinae
from five different animals.
FIGURE 3. Surviving RBPMSþ RGC count. (A, B) Mean 6 SEM number of surviving RBPMSþ RGC 56 days after ic microbead injection (A) or 21 days
after laser photocoagulation (B). Counts were conducted in a 0.33-mm2 region of retinal wholemounts, calculated as a composite average of 12
images taken at 1-, 2-, and 3-mm distances from the optic nerve head, four images per retinal petal (C; scale bar, 1 mm). Asterisks indicate significant
difference from injured/untreated at P < 0.05. (D) Representative images of RBPMSþ RGC from immunohistochemically stained retinal
wholemounts (scale bar: 250 lm). (E) Mean number of surviving RBPMSþ RGC 3 days after purification and culture. Asterisks indicate significant
difference at P < 0.01.
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RNA Sequencing
RNAseq was performed by System Biosciences (#CSEQ400A-1)
on sEV isolated from BMSC and fibroblasts (as detailed above),
three replicates per group. sEV RNA was quantified by
bioanalyzer small RNA assay (Agilent, Santa Clara, CA, USA)
and libraries constructed and sequenced using Illumina
NextSeq instrument with 1 3 75 bp single-end reads at an
approximate depth of 10 to 15 million reads per sample. A
scaling factor for a given sample was computed as the median
of the ratio of its read count for each gene over its geometric
mean across all samples. Raw read counts were divided by the
factor associated with their samples for normalization. Unlike
protein-coding genes/mRNA-seq data analysis in which only
uniquely mapped reads are considered, the miRNA pipeline
needs to allow multiple mapping of the same read to account
for the multiple copies. Thus, normalization was done on the
number of read alignments mapped to annotated gene features
across samples instead of the number of mapped reads.
The RNAseq data was displayed as a heat map of the log2-
fold change between fibroblast and BMSC sEV. A miRNA was
considered differentially abundant when the log2-fold change
was >2 or <2. Using Ingenuity Pathway Analysis software,
miRNA upregulated in BMSC sEV as well as their predicted
targets were mapped. Predicted targets were only considered if
they were experimentally observed findings and the mRNA/
miRNA sequences were present in both rat and human.
Statistics
All statistical tests were performed using SPSS 17.0 (IBM SPSS,
Inc., Chicago, IL, USA) and data presented as mean 6 SEM
with graphs constructed using Graphpad Prism 7.01 (Graph-
pad Prism, La Jolla, CA, USA). The Shapiro-Wilkes test was
used to ensure all data were normally distributed before
parametric testing using a 1-way ANOVA with a Tukey post
hoc test. Statistical differences were considered significant at
P values < 0.05.
RESULTS
BMSC-Secreted sEV
sEV isolated from human BMSC and fibroblasts were visualized
clearly by NanoSight and had a diameter of 100 to 120 nm, as
expected for exosomes (Fig. 1B). Very few larger EV were
detected and many of those that were detected were likely
exosomal aggregates. While NanoSight cannot distinguish sEV
from lipoprotein particles, Western blot data showed the
absence of ApoA1 and ApoB, markers of lipoproteins, while
markers of exosomes/sEV including Syntenin-1 and CD63 were
detectable (Supplementary Fig. S2).
Intracameral Microbeads and Laser
Photocoagulation of the Trabecular Meshwork Led
to Elevations in IOP
Microbeads delivered ic (Group 2) led to a significant rise in
IOP from 9.0 6 0.5 mm Hg (Day 0) to 20.5 6 2.4 mm Hg (Day
3), which remained high till the end of the experiment (14.2 6
2.0 mm Hg; Day 56; Fig. 2A). In contrast, IOP in uninjected
eyes (Group 1; 11.4 6 0.7 mm Hg; Day 0) did not change
significantly (10.3 6 0.6 mm Hg; Day 56). The injection of sEV
into the vitreous did not significantly (P < 0.05) affect the IOP
in ic microbead-injected eyes.
Laser photocoagulation (Group 3) led to a significant rise in
IOP from 9.0 6 0.4 mm Hg (Day 0) to 25.0 6 5.8 mm Hg (Day
7), which remained high until Day 17 (20.1 6 4.2 mm Hg) but
returned to baseline by the end of the experiment (11.1 6 1.4
mm Hg; Day 21; Fig. 2B). In contrast, IOP in uninjected eyes
(Group 1; 11.4 6 0.7 mm Hg; Day 0) did not change
significantly (11.7 6 1.8 mm Hg; Day 21). The injection of
sEV into the vitreous did not significantly (P < 0.05) affect the
IOP in laser-photocoagulated eyes.
Intravitreal BMSC sEV Promote Neuroprotection
The intact cohort of Sprague Dawley had an RGC density of
2703.2 6 73.3 RGC/mm2, which was similar to values obtained
in other studies.37,38 The number of RBPMSþ RGC at day 56 in
retinal wholemounts decreased significantly in the ic micro-
bead glaucoma model (1468.7 6 186.3 RGC/mm2) compared
with intact eyes (2703.2 6 73.3 RGC/mm2; Fig. 3A). Monthly
and weekly ivit injection of BMSC sEV provided significant
neuroprotection of RGC (2113.8 6 99.0 RGC/mm2, 2438.4 6
123.8 RGC/mm2, respectively) but not single injection (1485.7
6 27.3 RGC/mm2). Monthly and weekly ivit injection of
fibroblast sEV did not provide any neuroprotection to RGC
(1485.0 6 216.7 RGC/mm2, 1563.4 6 188.2 RGC/mm2,
respectively).
The number of RGC at day 21 in retinal wholemounts
decreased significantly in the laser photocoagulation glaucoma
model (1717.5 6 173.6 RGC/mm2) compared with intact eyes
(2703.2 6 73.3 RGC/mm2; Fig. 3B). Single and weekly ivit
injection of BMSC sEV provided significant neuroprotection of
RGC (2416.3 6 49.6 RGC/mm2; 2609.3 6 66.3 RGC/mm2,
respectively). This protective effect was partially abolished
after ivit injection of sEV isolated from BMSC transfected with
siAgo2 (2191.0 6 23.8 lm) but was still present if sEV isolated
from BMSC transfected with siScr were used (2550.2 6 109.7
lm). Successful knockdown of AGO2 with siAgo2 was
confirmed using Western blot (Supplementary Fig. S1). Single
and weekly ivit injection of fibroblast sEV did not provide any
neuroprotective effect to RGC (1975.6 6 6 RGC/mm2; 1850.6
6 108.9 RGC/mm2, respectively).
BMSC sEV Promote Neuroprotection of RGC
Partially Through Direct Mechanisms
Purified RGC die very rapidly, due to the necessary axotomy
when culturing along with the lack of present supporting cells.
Untreated purified cultures of RGC showed significant death
(25.7 6 1.7 RGC/well) relative to the 5000 RGC plated after 3
days in culture (Fig. 3E). While fibroblast sEV provided little to
no neuroprotective effect (60.7 6 13.0 RGC/well) BMSC sEV
elicited significant neuroprotection of (241 6 17.7 RGC/well).
Intravitreal BMSC sEV Preserve RNFL Thickness/
RGC Axonal Density
The thickness of the RNFL at day 21 decreased significantly in
the laser photocoagulation glaucoma model (31.8 6 1.1 lm)
compared with intact eyes (47.8 6 1.8 lm; Fig. 4). Single and
weekly ivit injection of BMSC sEV partially prevented
degenerative thinning of the RNFL (46.0 6 1.3 lm; 45.0 6
1.8 lm, respectively). This protective effect was not present
after ivit injection of sEV isolated from BMSC transfected with
siAgo2 (32.4 6 3.2 lm) but was still present if sEV isolated
from BMSC transfected with siScr were used (46.8 6 1.7 lm).
Single and weekly ivit injection of fibroblast sEV did not
prevent degenerative thinning of the RNFL (33.8 6 1.5 lm;
34.0 6 1.5 lm, respectively). There was no significant
difference between baseline recordings of all groups as well
as compared with intact at day 21 (data not shown).
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Intravitreal BMSC sEV Preserve pSTR Amplitude/
RGC Function
The amplitude of the pSTR at day 21 decreased significantly in
the laser photocoagulation glaucoma model (23.6 6 2.2 lv)
compared with intact eyes (55.5 6 0.7 lv; Fig. 5). Single and
weekly ivit injection of BMSC sEV prevented degenerative loss
of the pSTR (39.5 6 5.1 lv; 44.3 6 1.7 lv, respectively). This
protective effect was not present after ivit injection of sEV
isolated from BMSC transfected with siAgo2 (21.8 6 1.4 lv)
but was still present if sEV isolated from BMSC transfected with
siScr were used (38.2 6 2.1 lv). Single and weekly ivit
injection of fibroblast sEV did not prevent degenerative loss of
the pSTR (26.2 6 1.1; 25.5 6 2.5 lm, respectively). There was
FIGURE 4. RNFL thickness measurements of rats. (A) Mean 6 SEM RNFL thickness (lm) of rats measured by OCT in animals 21 days after laser
photocoagulation. Asterisks indicate significant difference from injured/untreated at P < 0.05. (B) RNFL measurements were taken from around the
optic nerve head (green circle; scale bar, 1 mm). (C) Representative OCT images of retina from which the RNFL (partially marked in red)
measurements were taken (scale bar: 200 lm).
FIGURE 5. ERG measurements of pSTR. (A) Mean 6 SEM amplitude (lv) of pSTR measured by ERG in animals 21 days after laser photocoagulation.
Asterisks indicate significant difference from injured/untreated at P < 0.05. (B) Representative traces of pSTR.
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FIGURE 6. miRNA abundance heat map profile. A comparison of the miRNA abundance profile in BMSC sEV and fibroblast sEV, displayed as a heat
map of the log2-fold change. Red indicates high comparative abundance, whereas green denotes low comparative abundance. Average log2-fold
change, an abundance value >200 reads per million (Asterisk) as well as P value are given. miRNA with >2 or <2 fold change only are shown.
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no significant difference between baseline recordings of all
groups as well as compared with intact at day 21 (data not
shown).
RNAseq Data
RNAseq detected 43 miRNA that were overabundant in BMSC
sEV by >2 (log2-fold change) compared with fibroblast sEV and
24 miRNA that were overabundant in fibroblast sEV by >2
compared with BMSC sEV (Fig. 6). Using ingenuity pathway
analysis, targets of the abundant miRNA were predicted (Fig. 7)
and the most enriched/targeted-signaling pathway identified
(Table 2).
DISCUSSION
The present study demonstrates that sEV derived from BMSC
promote significant neuroprotection of RBPMSþ RGC in two
FIGURE 7. miRNA targeting network. Schematic diagram displaying miRNA (red) upregulated in BMSC sEV and their experimentally observed
mRNA targets (yellow). Targeted genes were identified with ingenuity pathway analysis software and filtered for experimentally observed
interactions and, miRNA/mRNA sequences identified in both human and rat.
TABLE 2. Enriched Signaling Pathways Regulated by miRNA Abundant
in sEV
Term No. of Genes A/B P Value
IL-15 signaling 11/76 <0.001
JAK/STAT pathway 10/83 <0.001
HGF signaling 11/115 <0.001
PTEN signaling 11/119 <0.001
IL-8 signaling 13/197 <0.001
FGF signaling 10/90 <0.001
PDGF signaling 10/90 <0.001
EGF signaling 9/68 <0.001
Experimentally observed (1) and predicted (2) mRNA targets of
miRNA overabundant in BMSC sEV compared with fibroblast sEV,
displayed as the most enriched signaling pathways.
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separate and distinct models of glaucoma while protecting
against RNFL degeneration and pSTR loss. We attributed the
protective effect at least partially to the miRNA found within
sEV, a finding corroborated by our previous study in an ONC
rat model.22 We used two models of glaucoma in this study to
minimize the limitations that are present in every glaucoma
model. For example, the laser model suffers from being a short,
recoverable rise in IOP, whereas the ic microbead model, while
being characterized by a persistent rise in IOP, suffers from
opacities due to the beads in the anterior chamber, rendering
ERG and OCT unreliable. As not every animal responded with
elevated ocular hypertension, additional animals were run to
ensure each treatment subgroup consisted of five animals/10
eyes.
While MSC are currently undergoing clinical trials to test
their efficacy is various ocular diseases,13 their sEV have been
demonstrated safe in a recent clinical trial.39 Systemic delivery
of UCB-MSC–derived sEV into patients with chronic kidney
disease proved not only safe but also, significantly improved
kidney function while reducing inflammation.
Our previous study showed that sEV integrate into cells
within the ganglion cell layer, leading us to speculate that the
effect was direct, independent of non-RGC retinal cell
mediators. Our current findings demonstrate that in a purified
culture, RGC undergo the stereotypical 95% death after 4
days40,41 while treatment with sEV from BMSC, but not
fibroblasts, promoted significant RGC neuroprotection. This
further confirms that at least part of the neuroprotective effect
is mediated through direct sEV-RGC interactions. It should be
noted that the RGC are purified based on their expression of
Thy-1, a marker expressed in only 80% of RGC yet expressed in
cholinergic amacrine cells.42 While 5000 RGC are plated, only
approximately 30% attach to the plate.40 Thus, one criticism of
the purified RGC culture is it likely does not encompass every
RGC subtype.
The present study corroborates our previous findings that
showed BMSC sEV–mediated protection of RGC after ONC in
the rat. While a recent review highlights the growing trend in
ocular exosome/sEV research,43 few studies exist testing sEV as
a treatment in the eye. In a mouse retinopathy model
characterized by degeneration of vasculature and cessation of
their development, ivit delivery of exosomes derived from
endothelial colony-forming cells promoted significant angio-
genesis and reductions in avascular areas.44 Interestingly,
authors identified significant modulation of gene expression
in endogenous endothelial cells and related this effect to the
miRNA present in the exosomes. In a mouse model of
experimental autoimmune uveitis, systemic administration of
BMSC exosomes promoted significant reduction in inflamma-
tion.27 ivit injection of UCB-MSC or ADSC exosomes into a
mouse model of retinal laser injury promoted significant
neuroprotection while suppressing an inflammatory response
and improving visual function.30 Application of exosomes
derived from mouse fibroblast L cells shortly after optic nerve
injury promoted robust axonal regeneration, which was
strongly reduced in Wnt10b-deleted animals.45
It is still unclear how long exosomes/sEV remain after
administration into biological tissues, such as the vitreous. We
previously demonstrated therapeutic efficacy from weekly ivit
injections,22 whereas a separate study used a single intrave-
nous administration27 at a much higher dose (15 3 109
exosomes), demonstrating a therapeutic effect 21 days later in
an experimentally autoimmune uveitis model.
Ideally, ocular treatment should be long lasting to minimize
repeat injections and while there is a precedent for cell therapy
to have long lasting effects, no studies have assessed the
longevity of transplanted sEV. We used several different
treatment schedules in attempt to address this question,
injecting once, weekly, and monthly. As we previously
demonstrated,22 weekly ivit injections proved effective in all
measured endpoints. Interestingly, injections separated by 1
month also proved equally effective although a nonsignificant
trend toward a reduced neuroprotective effect compared with
weekly injections was observed in the microbead model.
Because the microbead model takes place over 56 days, we
also tested a single injection. The neuroprotective effects of
BMSC sEV were completely absent without a second injection
after 1 month, suggesting that BMSC sEV activity drops
dramatically after approximately 1 month in the vitreous. This
timeframe likely represents both the duration sEV reside in the
vitreous and the length of time the miRNA-mediated gene
regulation lasts.
AGO2 knockdown–mediated depletion of miRNA partially
inhibited the positive effects elicited by sEV evident by the
reduced RGC numbers, RNFL thickness, and pSTR amplitude;
with this suggestion that miRNA are integral to the mechanism,
we performed miRNAseq on BMSC sEV to aid in the potential
identification of candidates. We were able to identify candidate
miRNA that were more abundant in BMSC sEV in comparison
to fibroblast sEV. Several recent studies have analyzed the
miRNA content of MSC sEV. The first study identified 11 miRNA
present in UCB-MSC–derived sEV via microarray46 while the
second study detailed the top 100 most abundant miRNA using
RNAseq,47 demonstrating much overlap. These miRNA were
also detected by our RNAseq, however only MIR-100-5P and
MIR-106A-5P were significantly more abundant in BMSC sEV in
comparison to fibroblast sEV. A third study performed RNAseq
on human ADSC–derived sEV to identify the miRNA potentially
responsible for the observed anticancer properties.48 Several of
the miRNA that were detected were also identified in the
present study including MIR-1246 and MIR-269-5P however,
these miRNA were also found in equal or greater abundance
within fibroblast sEV, suggesting that they may not be integral
to the neuroprotective effects elicited. One miRNA detected
was also present in our data, MIR-486-5P, and was more
abundant (1.8-log2 fold change higher) in BMSC sEV compared
with fibroblast sEV, as well as being one of the most abundant
miRNA. This result has been further confirmed by a separate
RNAseq analysis performed on both human BMSC and ADSC23
as well as demonstrating that abundant miRNA differed
between each MSC source.
While abundance of particular BMSC-miRNA in comparison
to fibroblasts is critical for the identification of candidates, sEV-
mediated delivery of miRNA to the retina can only be effective
if the packaged miRNA are not already abundantly present in
the injured retina. For example, one recent study analyzed rat
retina 7 days after ocular hypertension,49 using microarray to
detect overabundant miRNA, whereas a separate study
analyzed 16 human retina from cadavers without any retinal
pathology, determining the 40 most highly abundant.50 From
these studies and the identified miRNA of the present study;
MIR-144-5P, MIR-126-5P, and MIR-100-5P were found to also
be overabundant in BMSC sEV. Because these miRNA are
already present in the retina, their contribution following sEV-
mediated delivery is likely minimal. In contrast, it has been
demonstrated that in the glaucomatous rat retina, several
miRNA are downregulated including mir-106b,51 which we
found to be abundant in BMSC sEV. It is feasible that
downregulation of miRNA has some role in the pathology of
glaucoma and delivery of these miRNA via BMSC sEV prevents
RGC degeneration. One caveat to the above studies is that
miRNA abundance was quantified in total retina as opposed to
purified RGC. Currently, no such study exists that provides a
detailed analysis of the miRNA present in RGC both before, and
after injury.
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While we believe that miRNA play an integral role in the
sEV-mediated neuroprotection of RGC, it is important to note
that miRNA have been found associated with other molecules
including protein aggregates52 and virus particles,53 both of
which could be found within sEV preparation. Because the
miRNA associated with these protein aggregates52 also
contains AGO2, it is possible that the diminished therapeutic
benefit after AGO2 knockdown is due to these miRNA as well
as sEV associated miRNA. Furthermore, after knockdown of
AGO2 (siAgo2), sEV still trended toward neuroprotection. As
siAgo2 yielded an incomplete (>70%) AGO2 knockdown, it is
possible that residual miRNA function was present and
responsible for this trend in RGC neuroprotection. Alterna-
tively, non-miRNA components of the BMSC sEV cargo may
indeed contribute some beneficial effects and include not only
mRNA but approximately 5000 proteins.24 Recently, BMSC-
derived sEV were shown to express an isoform of PDGF,
referred to as PDGF-D.54 Because PDGF was been shown to be
secreted from BMSC and promote significant RGC neuropro-
tection,14 it is possible that the PDGF loaded in sEV elicits
similar effects.
In conclusion, BMSC sEV promote neuroprotection and
functional preservation of RGC in two rat glaucomatous
models. While ivit injection of sEV did not directly affect IOP,
their neuroprotective efficacy makes them a good candidate as
an adjunctive therapy to IOP-lowering medications, and thus, a
potential future treatment for glaucoma.
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